<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774913</url>
  </required_header>
  <id_info>
    <org_study_id>195282</org_study_id>
    <nct_id>NCT04774913</nct_id>
  </id_info>
  <brief_title>Invest-CTO PCI Trial</brief_title>
  <official_title>Invest-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO&#xD;
      PCI registries where plaque modification has been performed in some patients, report this to&#xD;
      be safe, and associated with higher success rates at subsequent attempts.&#xD;
&#xD;
      It has never been investigated whether a planned investment procedure, with an intention that&#xD;
      both the initial and staged completion PCI are of shorter duration, could improve safety and&#xD;
      efficacy.&#xD;
&#xD;
      The investigators hypothesize that&#xD;
&#xD;
        1. A planned investment procedure in the treatment of CTOs will be associated with improved&#xD;
           patient safety&#xD;
&#xD;
        2. A planned investment procedure will be associated with improved cumulative procedure&#xD;
           success rates&#xD;
&#xD;
        3. A planned two stage procedure will be associated with improved patient experience&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single arm, international, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>CTO PCI Procedural success, Complete technical success plus the absence of an in-hospital major adverse cardiovascular event (MACE; death, MI, or clinically driven target vessel revascularization [TVR]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compositie safety endpoint</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Death, myocardial infarction and procedural related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTO PCI technical success</measure>
    <time_frame>At the end of staged CTO PCI completion procedure and within 3 months</time_frame>
    <description>Technical success is restoration of TIMI &gt;=2 antegrade flow with &lt;30% residual diameter stenosis within the CTO segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTO PCI investment procedural success</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Investment complete technical success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Clinical endpoint</measure>
    <time_frame>30 days, 3 &amp; 12 months</time_frame>
    <description>Cardiac death, MI , cardiovascular hospitalization and target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life-5 Dimensions</measure>
    <time_frame>Baseline, 3 and 12 months</time_frame>
    <description>5 item measure of mobility, self-care, usual activity, pain or discomfort, and anxiety or depression . Score 0-100, where high score better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle angina questionnaire (SAQ7)</measure>
    <time_frame>Baseline, 3 &amp; 12 months</time_frame>
    <description>3 domain score of physical limitation (SAQ7-PL), angina frequency (SAQ7-AF) and quality of life (SAQ7-QL). Score 0-100, where high score better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient related outcome measures (PROM)</measure>
    <time_frame>Through study completion, an average of 15 months.</time_frame>
    <description>Qualitative interviews</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Angina Pectoris</condition>
  <condition>Quality of Life</condition>
  <condition>PROM</condition>
  <arm_group>
    <arm_group_label>Invest CTO PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A pre-planned two staged procedure in high-risk CTO PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)</intervention_name>
    <description>CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks</description>
    <arm_group_label>Invest CTO PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Comply with the procedural and study follow-up schedule&#xD;
&#xD;
          -  Planned CTO PCI in accordance with the European and American appropriateness criteria.&#xD;
&#xD;
          -  CTO defined as high-risk&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-high risk CTO&#xD;
&#xD;
          -  Occlusion within a stent&#xD;
&#xD;
          -  Flush aorto-ostial occlusion of RCA and Left Main (LMS)&#xD;
&#xD;
          -  Limited arterial access precluding repeat procedure&#xD;
&#xD;
          -  Baseline non invasive testing showing non-viable target vessel territory&#xD;
&#xD;
          -  Contra-indication to dual antiplatelet therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prior radiation skin injury&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret B Mcentegart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Golden Jubilee National Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anja Øksnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Øksnes, MD</last_name>
    <phone>+4755975000</phone>
    <email>anao@helse-bergen.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Anja Øksnes, MD</last_name>
      <phone>+4755972191</phone>
      <email>anjaksnes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G814DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Margaret B Mcentegart, PhD</last_name>
      <phone>0141 951 5000</phone>
      <email>Margaret.mcentegart@gjnh.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

